Skip to content

US · 21 CFR

21 CFR Part 4

Regulation of Combination Products

eCFR, up to date as of 2026-11-12

Table of contents

  1. 4.1What is the scope of this subpart?
  2. 4.2How does FDA define key terms and phrases in this subpart?
  3. 4.3What current good manufacturing practice requirements apply to my combination product?
  4. 4.4How can I comply with these current good manufacturing practice requirements for a co-packaged or single-entity combination product?
  5. 4.100What is the scope of this subpart?
  6. 4.101How does the FDA define key terms and phrases in this subpart?
  7. 4.102What reports must you submit to FDA for your combination product or constituent part?
  8. 4.103What information must you share with other constituent part applicants for the combination product?
  9. 4.104How and where must you submit postmarketing safety reports for your combination product or constituent part?
  10. 4.105What are the postmarketing safety reporting recordkeeping requirements for your combination product or constituent part?
Cover page and contents (original)

Authority:21 U.S.C. 321, 331, 351, 352, 353, 355, 360, 360b-360f, 360h-360j, 360l, 360hh-360ss, 360aaa-360bbb, 360ddd, 360ddd-1, 371(a), 372-374, 379e, 381, 383, 394; 42 U.S.C. 216, 262, 263a, 264, 271.

Source:78 FR 4321, Jan. 22, 2013, unless otherwise noted.

Source: U.S. Office of the Federal Register / GPO — eCFR · U.S. federal government work — public domain (17 U.S.C. §105). eCFR is an editorial compilation, not an official legal edition of the CFR. · retrieved 2026-11-16

Weekly Newsletter

Get the week's FDA, EU and MFDS inspection findings

Every Monday we email the week's new findings and actions from the FDA, EMA, Health Canada and MFDS. Each one links to its record on our site, where you'll find the regulator's original document. We'll also let you know when the site gains new features. Unsubscribe any time with one click.

See recent findings first

Confirm by email to start · Unsubscribe any time